These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20701827)

  • 1. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat.
    Wadenberg MG; Manetti D; Romanelli MN; Arias HR
    Behav Brain Res; 2017 Aug; 333():129-134. PubMed ID: 28684359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Mar; 52(4):1179-87. PubMed ID: 17313962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats.
    Wiker C; Schilström B; Sandbäck C; Wadenberg ML; Svensson TH
    Int J Neuropsychopharmacol; 2008 Sep; 11(6):845-50. PubMed ID: 18405415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
    Erosa-Rivero HB; Bata-García JL; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
    Neuropharmacology; 2014 Jun; 81():176-87. PubMed ID: 24534110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Meltzer HY; Elkis H; Vanover K; Weiner DM; van Kammen DP; Peters P; Hacksell U
    Schizophr Res; 2012 Nov; 141(2-3):144-52. PubMed ID: 22954754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
    Barak S; Weiner I
    Neuropsychopharmacology; 2007 May; 32(5):989-99. PubMed ID: 16971898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.
    Marcus MM; Wiker C; Frånberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):891-903. PubMed ID: 19835668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.
    Schilström B; Ivanov VB; Wiker C; Svensson TH
    Neuropsychopharmacology; 2007 Jan; 32(1):43-53. PubMed ID: 16641937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal long term memory: effect of the cholinergic system on local protein synthesis.
    Lana D; Cerbai F; Di Russo J; Boscaro F; Giannetti A; Petkova-Kirova P; Pugliese AM; Giovannini MG
    Neurobiol Learn Mem; 2013 Nov; 106():246-57. PubMed ID: 24076274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
    Bontempi B; Whelan KT; Risbrough VB; Lloyd GK; Menzaghi F
    Neuropsychopharmacology; 2003 Jul; 28(7):1235-46. PubMed ID: 12700710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
    Siuciak JA; Chapin DS; McCarthy SA; Guanowsky V; Brown J; Chiang P; Marala R; Patterson T; Seymour PA; Swick A; Iredale PA
    Neuropharmacology; 2007 Feb; 52(2):279-90. PubMed ID: 16949622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
    Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice.
    Yano K; Koda K; Ago Y; Kobayashi H; Kawasaki T; Takuma K; Matsuda T
    Br J Pharmacol; 2009 Jan; 156(1):173-80. PubMed ID: 19133998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.